Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.49 DKK 0.4%
Market Cap: 640.2m DKK
Have any thoughts about
Bioporto A/S?
Write Note

Bioporto A/S
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioporto A/S
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Bioporto A/S
CSE:BIOPOR
Retained Earnings
-kr324.8m
CAGR 3-Years
-19%
CAGR 5-Years
-23%
CAGR 10-Years
-15%
Genmab A/S
CSE:GMAB
Retained Earnings
kr18.1B
CAGR 3-Years
30%
CAGR 5-Years
255%
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Retained Earnings
-kr5.9B
CAGR 3-Years
-25%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Retained Earnings
-€2.5B
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Retained Earnings
kr9.7B
CAGR 3-Years
23%
CAGR 5-Years
42%
CAGR 10-Years
31%
Saniona AB
STO:SANION
Retained Earnings
-kr884.7m
CAGR 3-Years
-29%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
No Stocks Found

Bioporto A/S
Glance View

Market Cap
640.2m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.3 DKK
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Bioporto A/S's Retained Earnings?
Retained Earnings
-324.8m DKK

Based on the financial report for Jun 30, 2024, Bioporto A/S's Retained Earnings amounts to -324.8m DKK.

What is Bioporto A/S's Retained Earnings growth rate?
Retained Earnings CAGR 10Y
-15%

Over the last year, the Retained Earnings growth was -9%. The average annual Retained Earnings growth rates for Bioporto A/S have been -19% over the past three years , -23% over the past five years , and -15% over the past ten years .

Back to Top